A176750 Share Price Performance
₩9,940.00
-3230.00 (-24.53%)
Price ₩9,940.00
Share Price₩9,940.00
DuChemBIOLtd (KOSDAQ:176750) Has A Pretty Healthy Balance Sheet
May 21
DuChemBIO Co.,Ltd. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
A176750 Community Narratives
There are no narratives available yet.
Recent A176750 News & Updates
DuChemBIO Co.,Ltd. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 256.08
- Gross Margin
- 33.85%
- Net Profit Margin
- 20.27%
- Debt/Equity Ratio
- 15.5%
DuChemBIO Co.,Ltd. Competitors
Snowflake Analysis
About A176750
- Founded
- 2002
- Employees
- 126
- CEO
- WebsiteView website
DuChemBIO Co.,Ltd. engages in the development, production, and sale of radiopharmaceutical products for cancer diagnosis and treatment in South Korea. Its products include FP-CIT for diagnosis of Parkinson’s disease and Parkinson's syndrome by measuring the density of dopamine transporters present in the brain striatum; F-DOPA for brain tumor diagnosis with neutralization technology; Neuraceq for diagnosis of Alzheimer's disease by measuring the distribution and density of beta amyloid in the brain; and Vizamyl for early diagnosis of beta amyloid in Alzheimer's disease. The company also offers FES, a solution for diagnosis of metastatic breast cancer and determination of estrogen receptor status; FACBC for prostate cancer diagnosis; FDG for the diagnosis of tumors; and NaF for the diagnosis of bone-related diseases. DuChemBIO Co.,Ltd. was founded in 2002 and is based in Seoul, South Korea.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
South Korean Market Performance
- 7 Days: 4.5%
- 3 Months: 15.8%
- 1 Year: 34.3%
- Year to Date: 44.6%
The market is up 4.5% over the last week, with the Information Technology sector leading the way, up 8.8%. In the last year, the market has climbed 34%. Earnings are forecast to grow by 24% annually. Market details ›